Merck & Co., Inc. — Director's Dealing 2019

Apr 10, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NGM BIOPHARMACEUTICALS INC (NGM)
CIK: 0001426332
Period of Report: 2019-04-08

Reporting Person: Merck & Co., Inc. (10% Owner)
Reporting Person: Merck Sharp & Dohme Corp. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-04-08	Common Stock	C	8833333	—	Acquired	8833333	Indirect
2019-04-08	Common Stock	P	4121683	$16.00	Acquired	12955016	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-04-08	Series E Convertible Preferred Stock	$	C	17666666	Disposed		Common Stock (8333333)	Indirect

Footnotes

F1: Each share of Series E Convertible Preferred Stock automatically converted into one-half (0.5) of a share of common stock immediately prior to the closing of the Issuer's initial public offering, and has no expiration date.

F2: These securities are owned directly by Merck Sharp & Dohme Corp., which is a direct, wholly owned subsidiary of Merck & Co., Inc. ("Merck"). Merck is an indirect beneficial owner of the reported securities.